HopeStage
Back to all studies
TerminatedNCT00211302

Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS)

Medication studyAges 18–65United States
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 65 years.

Listed locations
ShreveportSee all locations and recruitment

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateAugust 2003
Recruitment status
Terminated
Enrollment listed in the registry
8
Sponsor
Louisiana State University Health Sciences Center Shreveport
Sponsor type
University
Study type
Drug
Intervention type
Drug
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT00211302
Official title
Show the full official title

Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia. (BMS)

Recruitment & locations

Terminated

Shreveport

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Louisiana State University Health Sciences Center Shreveport, a university.

Does this study involve medication?

Yes. The study involves medication, including aripiprazole.

Who can participate?

Listed age limits: 18 years to 65 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies